{"id":"parecoxib-and-remifentanil","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1206690","moleculeType":"Small molecule","molecularWeight":"370.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Parecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby decreasing pain and inflammation without affecting platelet function. Remifentanil is a synthetic opioid that binds to mu-opioid receptors in the central nervous system, providing rapid onset and offset analgesia and sedation due to its ester metabolism. Together, they provide multimodal analgesia for perioperative pain management.","oneSentence":"Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:49.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Perioperative pain management and analgesia"},{"name":"Postoperative pain relief"}]},"trialDetails":[{"nctId":"NCT07337135","phase":"NA","title":"Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery","status":"COMPLETED","sponsor":"Hospital dos Lusíadas","startDate":"2023-10-02","conditions":"Morbid Obesity, Postoperative Pain, Opioid Free Anesthesia","enrollment":60},{"nctId":"NCT04767256","phase":"NA","title":"Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2021-03-01","conditions":"Dexamethasone, Dexmedetomidine, Nerve Block","enrollment":120},{"nctId":"NCT03135795","phase":"PHASE4","title":"The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2017-02-06","conditions":"Epigenetics","enrollment":100},{"nctId":"NCT00785863","phase":"PHASE4","title":"Modulation of Remifentanil-induced Postinfusion Hyperalgesia","status":"COMPLETED","sponsor":"Ullevaal University Hospital","startDate":"2008-12","conditions":"Hyperalgesia, Secondary","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dynastat"],"phase":"marketed","status":"active","brandName":"Parecoxib and remifentanil","genericName":"Parecoxib and remifentanil","companyName":"Ullevaal University Hospital","companyId":"ullevaal-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation. Used for Perioperative pain management, Postoperative analgesia.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2002-03-22T00:00:00.000Z","mah":"Pfizer Europe MA EEIG","brand_name_local":"Dynastat","application_number":"EMEA/H/C/000381"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}